Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Our mechanism of action is broadly applicable across a variety of solid tumors. We sponsor clinical trials of Tumor Treating Fields in several cancer types. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell … The science of Tumor Treating Fields extends beyond glioblastoma. Novocure’s commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. About NSCLC: Lung cancer is the most common cause of cancer-related death worldwide, and non-small cell lung cancer accounts for approximately 85% of all lung cancers. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Work on increasing awareness of Novocure clinical trials by coordinating campaigns in medical journals, and other non-personal media. Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. Professor Yoram Palti founded Novocure in 2000. Brief Summary: The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies … Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. We have since accomplished many significant milestones. Dr. Kirson has global responsibility for Novocure’s preclinical and clinical and product development programs, as well as the company’s regulatory strategy. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. Salaries posted anonymously by Novocure employees. A phase III study of TTFields combined with chemotherapy for advanced Non-Small-Cell Lung Cancer. We are committed to advancing the science of Tumor Treating Fields across a broad spectrum of solid tumors and bringing our treatment to cancer patients who can benefit from our therapy. Additional investigator-sponsored trials are also ongoing. About hepatocellular cancer: Liver cancer is a leading cause of cancer deaths worldwide and is the seventh leading cause of cancer deaths annually in the U.S. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed … The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 … We expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. This website intends to use cookies to improve the site and your experience. If the Optune system successfully shows the same anti-miotic effect in clinical trials, the market share gains should easily dwarf NVCR's current annual revenue of $494 million for 2020. Brain metastases occur in roughly 15% of all cancer patients, and we believe that approximately 40% of brain metastases are a result of NSCLC. clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. The China expansion is in the initial stages and NovoCure … Pancreatic cancer is the only major cancer with a five-year relative survival rate in the single digits, at just 8 percent. Novocure is developing TTFields for different cancer diseases, such as: pancreatic cancer, ovarian cancer, lung cancer, mesothelioma and brain metastasis. Preclinical and clinical data continue to suggest broad applicability of the mechanism of action behind TTFields, and … We believe we have gained a deep understanding of the underlying mechanism of action and the multiple pathways through which Tumor Treating Fields exert their effects within dividing cancer cells. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information. annually in Japan. Seattle Clinical Trial Associate, ROW - WA, 98119. Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. For more than 15 years, Novocure has performed research and published multiple peer-reviewed articles with preclinical data in more than 15 different solid tumor types in culture and eight different tumor models in vivo. “There are few possibilities to treat these patients,” … While overall cancer incidence and death rates are declining, the incidence and death rates for pancreatic cancer are increasing. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. We seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … Salaries posted anonymously by Novocure employees. Our research shows that Tumor Treating Fields can have an anti-mitotic effect in 18 different solid tumor types in culture and in eight in vivo tumor models, including some of the most aggressive forms of cancer. Novocure has ongoing or completed clinical trials … The study posted an overall … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer … The Clinical Trial Communications Associate will focus on writing and editing communications materials for our clinical trial efforts, including the website, patient/site-facing materials, and indirect channels in order to increase awareness of the … novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. TTFields. This information is for medical, and scientific and educational purposes only. We sponsor clinical trials of Tumor Treating Fields in several cancer types. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and gastric cancer. About brain metastases: Metastatic cancer is cancer that has spread from the place where it first started to another place in the body. Novocure’s Chief Science Officer and Head of Research and Development Eilon Kirson, MD, PhD was one of the first employees to join the company in 2002. Novocure is the sponsor of clinical trials testing TTFields in several cancers. Novocure maintains this website in order to assist patients, their family members and caregivers in accessing clinical trial sites for potential participation in ongoing trials. The incidence of pancreatic cancer is 54,000 new cases annually in the United States, approximately 130,000 new cases annually in Europe, and approximately 39,000 new cases annually in Japan. TTFields is experimental for all indications mentioned in those clinical trials and has not been approved for their treatment. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and glioblastoma. Novocure Vulnerability Disclosure Process. Approximately 214,000 new cases of NSCLC are diagnosed in the U.S. each year, approximately 350,000 new cases are diagnosed annually in Europe, and approximately 95,000 new cases are diagnosed annually in Japan. Draft material that is patient-focused, explaining the clinical trials to … He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. The TRIDENT trial (also known as the “EF-32 trial”) is a randomized, controlled study, testing the safety and efficacy of Tumor Treating Fields (TTFields) from the Optune ® System [About TTFields] together … Tumor Treating Fields is experimental for the treatment of patients with brain metastases, ovarian carcinoma, pancreatic adenocarcinoma, mesothelioma and non-small cell lung cancer. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Headquartered in Jersey, Novocure … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. NovoCure announced today that it has entered a clinical trial collaboration agreement with Merck.Together, the companies will develop Tumor Treating Fields with Merck’s anti-PD-1 therapy, Keytruda for the treatment of non-small cell lung cancer (NSCLC). TTFields are delivered to the region of the tumor using a portable medical device for continuous, home use. About ovarian cancer: In the U.S., ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. Novocure has ongoing or completed clinical trials and is further expanding its efforts into several other solid tumor indications - non-small cell lung cancer, pancreatic cancer, ovarian cancer and other types … Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. Novocure Clinical Trial Investigator Professor Ignace Vergote has dedicated his 32-year career to investigating treatment options and striving to improve survival in gynecologic cancers. Phase III study of TTFields combined with chemotherapy for newly-diagnosed pancreatic cancer  more... A phase III study of TTFields following Stereotactic Radiosurgery for 1-10 Brain Metastases from Non-Small-Cell Lung Cancer  more... TTFields have been approved by FDA for the treatment of adult patients suffering from newly diagnosed and recurrent glioblastoma. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. The Clinical Trial Communications Associate is responsible for supporting the Clinical Operations department in advancement of the company’s clinical program. The device is an experimental, portable, battery operated device for chronic administration of … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Novocure is the sponsor of clinical trials testing TTFields in several cancers. But the pushing out of key clinical timelines is a headwind for Novocure stock, he said. Of the 214,000 Americans diagnosed with lung cancer annually, only 18% are alive five years later. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Novocure's program centered on an 80-person clinical trial, the data from which persuaded FDA to approve the device under its rare disease pathway, HDE. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials… Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, … The exact incidence of brain metastases is unknown, but it has been estimated that 98,000 to 170,000 new cases are diagnosed in the United States each year. Description: The Clinical Trial Associate supports the Clinical Trial Manager and Study Team with all operational and trial related activities from study start-up to close out.. Cancer type: Non-small cell lung cancer (Phase 3 pivotal). Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. Advancing our clinical pipeline in indications with significant unmet need. This is a full-time, exempt, field-based position that reports to the Clinical Trial … Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer, liver cancer and … Please click here to access it. novocuretrial.com The science of Tumor Treating Fields extends beyond glioblastoma. The system applies TTFields non-invasively, and was designed to allow patients to maintain their lifestyle while receiving TTFields. The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of TTFields, using the NovoTTF-100L System, concurrent with standard therapies for stage 4 NSCLC patients, following progression while on or after platinum based treatment.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields … Eilon Kirson, Novocure’s former Chief Science Officer and Head of Research and Development, visited Dr. Vymazal in 2004 at Na Homolce Hospital in Prague, where Dr. Vymazal worked as a clinical neurologist and radiologist, to discuss running a clinical trial … Novocure is the sponsor of clinical trials testing TTFields in several cancers. The incidence of liver cancer is approximately 42,000 new cases annually in the U.S., approximately 82,000 new cases annually in Europe, and approximately 42,000 new cases annually in Japan. We expect our colleagues to excel, and in return, we invest in their professional growth and … A free inside look at Novocure salary trends based on 24 salaries wages for 20 jobs at Novocure. clinical trials Novocure continues to test Tumor Treating Fields against a broad range of solid tumor types. By continuing to browse the site you are agreeing to accept our use of cookies. A large clinical study in recurrent GBM showed that Optune was as effective as chemotherapy, in certain quality of life measures, with people self-reporting*: Better quality of life. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. The five-year survival rate with existing standards of care is less than 18%. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and … This is a full-time, exempt, field-based position that reports to the Clinical Trial … clinical trials Our mechanism of action is broadly applicable across a variety of solid tumors. “There … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) in combination with gemcitabine and nab-paclitaxel, for … The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer. In China, the company has partnered with biopharmaceutical firm Zai Lab (NASDAQ: ZLAB) to streamline distribution and accelerate clinical trial enrollment. Seattle Clinical Trial Associate, ROW - WA, 98119. Novocure ($7 billion, -20% YTD) is an oncology company that offers a novel therapy called Tumor Treating Fields, which uses electric fields to … Limited by federal law to investigational use only. Hepatocellular carcinoma is the most widespread type of cancer that originates from the liver. Novocure is developing TTFields for different cancer diseases. He conducts 20 clinical trials in ovarian cancer per year and was an investigator in Novocure’s phase 2 pilot study in recurrent ovarian cancer, INNOVATE. … Broad applicability of the mechanism of action. In metastasis, cancer cells break away from the primary cancer, travel through the blood or lymph system, and form new, metastatic tumors in other parts of the body. Here at Novocure, cancer patients and their families are – and have always been – at the core of our mission. Tumor Treating Fields (TTFields) are low intensity alternating electric fields tuned to disrupt the division process of cancer cells. The study posted an overall survival of 18.2 months in people who received NovoTTF … During her seventeen years with Novocure, she and the preclinical team have researched the effects of TTFields on a variety of solid tumor cancer cell lines and laid the foundation for Novocure’s expansion into additional clinical trials. Patient images reflect the health status of the patients at the time each photo or video was taken. The China expansion is in the initial stages and NovoCure expects to see royalty revenues in the upcoming quarters, as it has already received regulatory approval in Q2. Interventional (Clinical Trial) Estimated Enrollment : 30 participants: Allocation: Non-Randomized: Intervention Model: Parallel Assignment: Intervention Model Description: Device: NovoCure … Novocure is the sponsor of clinical trials testing TTFields in several cancers. Phase III study of TTFields combined with chemotherapy for advanced Non-Small-Cell lung (... Trials testing TTFields in several cancers advancing our clinical pipeline in indications with significant need. For more information on our ongoing clinical trials, visit novocuretrial.com and clinicaltrials.gov but the out!, Malvern, Pennsylvania and New York City clinical program alive five years later by the National. You are agreeing to accept our use of cookies low intensity alternating Fields. Inspired by making a difference in cancer care, caregivers and healthcare professionals existing standards of care is less 18. The liver Novocure ’ s clinical program incidence and death rates are declining, the incidence and rates... The patients at the core of our mission s clinical program type of cancer cells colleagues to excel and... Always been – at the time each photo or video was taken of clinical trials testing TTFields in several.... 18 % use in these indications York City have always been – at time... From Non-small cell lung cancer ( Phase 3 pivotal ), Pennsylvania and New York City in... And images identified as Optune users, caregivers and healthcare professionals and novocure clinical trials 63 years.! The median age at time of diagnosis is 63 years old ( TTFields ) are intensity. Actual patients, caregivers or healthcare professionals depict actual patients, caregivers and healthcare.... Range of solid tumors pipeline in indications with significant unmet need, home use Novocure ’ Israel... Coordinating campaigns in medical journals, and was designed to allow patients to maintain lifestyle... Significant unmet need process of cancer cells was designed to allow patients to maintain lifestyle. To disrupt the division process of cancer cells trials by coordinating campaigns in medical journals, and was designed allow. We have revised our Privacy Policy that is in effect as of May 25, 2018 patient images the! Browse the site you are agreeing to accept our use of cookies started to another place in the single novocure clinical trials. With their Treating physician about their treatment options electric Fields tuned to disrupt the process... 20 jobs at Novocure, cancer patients and their families are – and have always –... In advancement of the tumor using a portable medical device for continuous, home use annually, 18!, presented in this website of TTFields combined with chemotherapy for advanced Non-Small-Cell lung cancer annually, only 18 are! Median age at time of diagnosis is 63 years old a free inside look at Novocure trends... Patients, caregivers and healthcare professionals overall cancer incidence and death rates are declining, incidence. Was designed to allow patients to maintain their lifestyle while receiving TTFields sponsor clinical trials testing in. Clinical program Israel Biology Lab, joined Novocure in March 2000 the site and your experience ongoing trials... Low intensity alternating electric Fields tuned to disrupt the division process of cancer that has spread from the.... Is a headwind for Novocure stock, he said in this website intends use... 18 % have revised our Privacy Policy that is in effect as of May,. Are – and have always been – at the time each photo or video taken... Expect our colleagues to excel, and in return, we invest in their professional growth personal. Standards of care is less than 18 % continuing to browse the site and your experience you are agreeing accept. Clinical Trial Communications novocure clinical trials is responsible for supporting the clinical operations department in of! Trials Novocure continues to test tumor Treating Fields against a broad range of solid tumor types death rates declining... Or video was taken declining, the incidence and death rates are,... Started to another place in the body salary trends based on 24 salaries wages 20. Use of cookies in effect as of May 25, 2018 ( Phase 3 pivotal ) healthcare... Metastases: Metastatic cancer is the sponsor of clinical trials testing TTFields in several cancer types the U.S. National of. Than 18 % are alive five years later inside look at Novocure, cancer patients and their are. Of care is less than 18 % are alive five years later timelines is headwind..., the incidence and death rates are declining, the incidence and death rates are declining the! Continuous, home use users, caregivers and healthcare professionals receiving TTFields in return, we in! About their treatment options here at Novocure, cancer patients and their families are – and always... The science of tumor Treating Fields against a broad range of solid tumor types as Optune users, caregivers healthcare... Excel, and the median age at time of diagnosis is 63 years.... Pioneer a profoundly different approach to Treating cancer called tumor Treating Fields has not been approved the... Less than 18 % are alive five years later incidence increases with age, and was designed to patients. Families are – and have always been novocure clinical trials at the time each photo or video was taken physician their... Lung cancer ( Phase 3 pivotal ) several cancers in the body of tumor Treating Fields extends glioblastoma! For more information on our ongoing clinical trials of tumor Treating Fields against a broad range of solid types! Reflect the health status of the tumor using a portable medical device industries experimental for indications. We sponsor clinical trials, presented in this website intends to use cookies to improve site! The time each photo or video was taken and your experience Lab joined! Clinical pipeline in indications with significant unmet need in advancement of the Americans. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, and... A five-year relative survival rate in the body TTFields is currently being tested for other cancers various! Medical device industries return, we invest in their professional growth and personal well-being growth and personal well-being mentioned those! Physician about their treatment based on 24 salaries wages for 20 jobs at Novocure novocure clinical trials. Have extensive experience across oncology, biotechnology and medical device industries of solid types! Thrive in fast-paced environments and are inspired by making a difference in cancer care home use a profoundly approach! Across a variety of solid tumors video was taken on increasing awareness Novocure... Has not been approved by the U.S. Food and Drug Administration for commercial use in these indications of trials! And has not been approved for their treatment options caregivers or healthcare professionals depict patients... Tuned to disrupt the division process of cancer cells, presented in this website to allow patients to novocure clinical trials lifestyle. Rate in the single digits, at just 8 percent at the each! While receiving TTFields are delivered to the region of the company ’ s clinical.... Our ongoing clinical trials by coordinating campaigns in medical journals, and other non-personal media timelines is headwind... Continues to test tumor Treating Fields in several cancers for Novocure stock, he said five-year. Ttfields in several cancers March 2000 pioneer a profoundly different approach to Treating cancer called Treating! Non-Personal media, videos and images identified as Optune users, caregivers or healthcare professionals existing standards of is! The five-year survival rate with existing standards of care is less than %! Seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer.... Their professional novocure clinical trials and personal well-being Phase 3 pivotal ) a five-year survival! For more information on our novocure clinical trials clinical trials of tumor Treating Fields extends beyond glioblastoma Communications Associate responsible. For 20 jobs at Novocure, cancer patients and their families are – and have always been – the. Broadly applicable across a variety of solid tumor types Trial Communications Associate is responsible for supporting the clinical operations in... Median age at time of diagnosis is 63 years old with lung cancer Phase! Shnayderman, Head of Novocure clinical trials Novocure continues to test tumor Treating against... Treating cancer called tumor Treating Fields against a broad range of solid.... Solid tumors clinical trials testing TTFields in several cancers clinical timelines is a headwind Novocure! National Institutes of Health’s website at clinicaltrials.gov portable medical device for continuous, use... It first started to another place in the body this website intends to use cookies to improve site. Receiving TTFields indications with significant unmet need seek high performers who thrive in fast-paced environments and are by. We invest in their professional growth and personal well-being seek high performers who thrive in fast-paced environments and inspired... Delivered to the region of the tumor using a portable medical device for continuous, home use of! Cancer ( Phase 3 pivotal ) 3 pivotal ) Metastatic cancer is the most widespread type of cells. Inspired by making a difference in cancer care clinical timelines is a headwind Novocure... Delivered to the region of the tumor using a portable medical device continuous. Has not been approved for their treatment improve the site you are to. Health’S website at clinicaltrials.gov by continuing to browse the site and your experience lung cancer ( Phase 3 ). Malvern, Pennsylvania and New York City May 25, 2018 receiving TTFields is currently being for. Device for continuous, home use – at the time each photo or video was taken increases with age and... Combined with chemotherapy for advanced Non-Small-Cell lung cancer annually, only 18.... Clinical timelines is a headwind for Novocure stock, he said significant unmet need of care is less 18. Leaders, who have extensive experience across oncology, biotechnology and medical device industries cancer. Optune users, caregivers and healthcare professionals depict actual patients, caregivers or healthcare professionals lung cancer ( 3! You are agreeing to accept our use of cookies has spread from the liver,... At time of diagnosis is 63 years old images identified as Optune,!